140 related articles for article (PubMed ID: 19583677)
1. CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Jin SK; Kang TS; Eom SO; Kim JI; Lee HJ; Roh J
J Clin Pharm Ther; 2009 Aug; 34(4):437-46. PubMed ID: 19583677
[TBL] [Abstract][Full Text] [Related]
2. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Lawson EB; Wu JC; Baldwin RM; Ingelman-Sundberg M; Rosenborg S; Yim DS; Yin OQ; Capparelli EV; Ma JD
Eur J Clin Pharmacol; 2012 Apr; 68(4):407-13. PubMed ID: 22009190
[TBL] [Abstract][Full Text] [Related]
4. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Br J Clin Pharmacol; 2008 May; 65(5):767-74. PubMed ID: 18294333
[TBL] [Abstract][Full Text] [Related]
5. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Isaza C; Henao J; Martínez JH; Sepúlveda Arias JC; Beltrán L
BMC Clin Pharmacol; 2007 Jul; 7():6. PubMed ID: 17623107
[TBL] [Abstract][Full Text] [Related]
6. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Eur J Clin Pharmacol; 2004 Nov; 60(9):623-8. PubMed ID: 15448955
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
10. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population.
Wang JH; Li PQ; Fu QY; Li QX; Cai WW
Clin Exp Pharmacol Physiol; 2007; 34(5-6):421-4. PubMed ID: 17439410
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
13. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.
Zhang D; Wang X; Yang M; Wang G; Liu H
Xenobiotica; 2011 Jun; 41(6):511-7. PubMed ID: 21521077
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole disposition in children following single-dose administration.
Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
[TBL] [Abstract][Full Text] [Related]
16. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
17. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Fan L; Wang G; Wang LS; Chen Y; Zhang W; Huang YF; Huang RX; Hu DL; Wang D; Zhou HH
Acta Pharmacol Sin; 2007 Oct; 28(10):1685-92. PubMed ID: 17883958
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
[TBL] [Abstract][Full Text] [Related]
19. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
